Barclays
DNA icon

Barclays’s Ginkgo Bioworks DNA Stock Holding History

Barclays’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.9K Sell
7,978
-56,487
-88% -$470K ﹤0.01% 4330
2025
Q4 		$536K Buy
64,465
+6,665
+12% +$71.8K ﹤0.01% 3806
2025
Q3 		$843K Sell
57,800
-18,328
-24% -$219K ﹤0.01% 3470
2025
Q2 		$856K Buy
76,128
+28,712
+61% +$222K ﹤0.01% 3440
2025
Q1 		$270K Sell
47,416
-6,750
-12% -$68.8K ﹤0.01% 3886
2024
Q4 		$532K Buy
54,166
+42,224
+354% +$362K ﹤0.01% 3784
2024
Q3 		$97.3K Buy
11,942
+8,495
+246% +$85.1K ﹤0.01% 4582
2024
Q2 		$46.1K Sell
3,447
-6,227
-64% -$186K ﹤0.01% 4239
2024
Q1 		$449K Buy
9,674
+457
+5% +$23.7K ﹤0.01% 3663
2023
Q4 		$623K Sell
9,217
-166
-2% -$10.2K ﹤0.01% 3746
2023
Q3 		$679K Buy
9,383
+729
+8% +$58.3K ﹤0.01% 2600
2023
Q2 		$644K Sell
8,654
-11,001
-56% -$651K ﹤0.01% 2594
2023
Q1 		$1.05M Sell
19,655
-2,178
-10% -$138K ﹤0.01% 2700
2022
Q4 		$1.48M Buy
21,833
+2,754
+14% +$253K ﹤0.01% 2479
2022
Q3 		$2.38M Buy
19,079
+11,400
+148% +$1.36M ﹤0.01% 1629
2022
Q2 		$731K Buy
7,679
+6,693
+679% +$816K ﹤0.01% 2582
2022
Q1 		$159K Buy
+986
New +$192K ﹤0.01% 3557

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's DNA Position: Q1 2026 in Review

Barclays reduced its Ginkgo Bioworks (DNA) stake by 88% in Q1 2026, selling an estimated $470K and leaving 7,978 shares worth $48.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4330.

Barclays first reported a position in DNA in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.38M in Q3 2022. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Barclays held 7,978 shares of Ginkgo Bioworks worth $48.9K as of Q1 2026.
  • Barclays sold 56,487 Ginkgo Bioworks shares in Q1 2026, an estimated $470K.
  • Ginkgo Bioworks made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4330 holding.
  • Barclays first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Ginkgo Bioworks position peaked at $2.38M in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.